Insulet's next-gen insulin pump gains 510(k) clearance; Italian researchers eye wood as hip replacement material;

 @FierceMedDev: InVivo Therapeutics is seeing an HDE for its biopolymer scaffolding product. Clinical trial starts in early 2013. News | Follow @FierceMedDev

@MarkHFierce: Zoll says its "temperature management solution" device treated 17 pilgrims with heat stroke on their way to Mecca. More | Follow @MarkHFierce

 @DamianFierce: Barack Obama has no interest in a delay on the 2.3% medical device tax. News | Follow @DamianFierce

> Insulet won FDA 510(k) clearance for its next-generation OmniPod insulin pump. Release

> SQI Diagnostics lost $6.3 million in its fiscal year ending Sept. 30, 2012, an improvement over the $10.7 million net loss reported in fiscal 2011. Release

> Researchers at Rice University and Texas Children's Hospital are successfully using bioscaffolding seeded with living cardiac cells to heal the hearts of infants suffering from birth defects. Release

> With all the problems that metal hip replacements have been causing, Italian researchers are exploring whether wood might make a better--and safer--hip material. Item

> Meridian Bioscience ($VIVO) says it has completed beta trials for two new illumigene diagnostic tests designed to detect gonorrhea and chlamydia DNA from swab and urine samples. Item

> Mindray Medical ($MR), China's largest medical device company, seeking to build its reputation as a major industry player, made its case recently at the Radiological Society of North America conference in Chicago. Story

> A shark's skin has bacterial-resistant properties, and it is the model for a new synthetic coating designed to cover medical devices and hospital equipment. Story

> Zoll Medical Corp. is touting the fact that its intravascular temperature management device successfully treated 17 pilgrims who suffered heat stroke on the annual pilgrimage to Mecca. Release

Biotech News

 @FierceBiotech: Genentech readies for groundbreaking $100M trial of Alzheimer's therapy. News | Follow @FierceBiotech

@JohnCFierce: Cowen out with list of top 10 potential surprises in '13, includes early OK on asfotase; restricting CRPC drugs to metastatic patients. List | Follow @JohnCFierce

@RyanFierce: EMA committee shoots down Sanofi's cholesterol drug mipomersen. News | Follow @RyanMFierce

> Cowen lists top 10 potential surprise catalysts for 2013. Report

> Roche gains blockbuster backing for breast cancer therapy in Europe. Story

Pharma News

@FiercePharma: WSJ: Pfizer animal health IPO could happen next month. Story | Follow @FiercePharma

> Roche looks to earn even more from Perjeta with EU nod. Article

> Lundbeck anti-binge drinking drug gets EU OK. Story

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.